NASDAQ:CARA Cara Therapeutics - CARA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.91 +0.02 (+0.41%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.90▼$5.0650-Day Range$4.89▼$12.2752-Week Range$4.77▼$13.97Volume824,247 shsAverage Volume604,204 shsMarket Capitalization$264.85 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Cara Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside246.2% Upside$17.00 Price TargetShort InterestHealthy12.19% of Float Sold ShortDividend StrengthN/ASustainability-1.39Upright™ Environmental ScoreNews Sentiment1.33Based on 3 Articles This WeekInsider TradingSelling Shares$73,938 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.61) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.80 out of 5 starsMedical Sector59th out of 1,004 stocksPharmaceutical Preparations Industry18th out of 489 stocks 4.3 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Cara Therapeutics has a forecasted upside of 246.2% from its current price of $4.91.Amount of Analyst CoverageCara Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.19% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Cara Therapeutics has recently decreased by 6.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.Environmental SustainabilityThe Environmental Impact score for Cara Therapeutics is -1.39. Previous Next 4.1 News and Social Media Coverage News SentimentCara Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cara Therapeutics this week, compared to 1 article on an average week.Search Interest14 people have searched for CARA on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows8 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,938.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions69.26% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($1.61) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cara Therapeutics (NASDAQ:CARA) StockCARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.Read More Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARA Stock News HeadlinesMarch 26, 2023 | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Shares Pass Below 200 Day Moving Average of $10.11March 14, 2023 | finance.yahoo.comCara Therapeutics Releases Inaugural Environmental, Social, and Governance ReportApril 1, 2023 | Investorplace Media (Ad)5 Stocks to Buy ImmediatelyAmerica’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. March 11, 2023 | finance.yahoo.comThings Look Grim For Cara Therapeutics, Inc. (NASDAQ:CARA) After Today's DowngradeMarch 8, 2023 | msn.comCara Therapeutics downgraded at BofA on sales forecast for KorsuvaMarch 8, 2023 | finance.yahoo.comCara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | msn.comAnalyst Ratings for Cara TherapeuticsMarch 7, 2023 | finance.yahoo.comCara Therapeutics stock sinks on larger-than-expected Q4 earnings missApril 1, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.March 7, 2023 | benzinga.comCara Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS and sales results.March 7, 2023 | msn.comCara Therapeutics Gets Price Targets Cuts By Analysts After Weak Q4 ResultsMarch 7, 2023 | marketwatch.comCara Therapeutics Shares Tumble Premarket After 4Q Report >CARAMarch 7, 2023 | finance.yahoo.comMeta’s stock up on report of more layoffs, and WeightWatchers telehealth deal gives it access to promising obesity drug marketMarch 7, 2023 | finanznachrichten.deCara Therapeutics, Inc.: Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial ResultsMarch 6, 2023 | finance.yahoo.comThese 2 Stocks Are Plunging After Hours MondayMarch 3, 2023 | msn.comEarnings Outlook For Cara TherapeuticsFebruary 27, 2023 | finance.yahoo.comWill Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should KnowFebruary 23, 2023 | seekingalpha.comCara Therapeutics: Difelikefalin Struggles To Stand Out With Uncertain ProspectsFebruary 21, 2023 | finance.yahoo.comCara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023February 15, 2023 | finance.yahoo.comCara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Cut Their EPS Forecasts SubstantiallyFebruary 8, 2023 | finance.yahoo.comCara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of MedicineJanuary 17, 2023 | finance.yahoo.comCara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023January 3, 2023 | finance.yahoo.comCara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 29, 2022 | finance.yahoo.comCara Therapeutics (NASDAQ:CARA shareholders incur further losses as stock declines 8.8% this week, taking three-year losses to 35%December 24, 2022 | forbes.comCara TherapeuticsDecember 23, 2022 | msn.comCannabis Stock Movers For December 23, 2022December 17, 2022 | finance.yahoo.comCara Therapeutics, Inc. (CARA) Stock Historical Prices & Data - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARA Company Calendar Last Earnings11/07/2021Today3/31/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees84Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+238.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-85,470,000.00 Net Margins-204.16% Pretax Margin-204.16% Return on Equity-45.46% Return on Assets-40.40% Debt Debt-to-Equity RatioN/A Current Ratio7.20 Quick Ratio7.10 Sales & Book Value Annual Sales$41.87 million Price / Sales6.48 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book1.71Miscellaneous Outstanding Shares53,940,000Free Float52,217,000Market Cap$271.32 million OptionableOptionable Beta0.99 Key ExecutivesChristopher PosnerPresident, Chief Executive Officer & DirectorRyan D. MaynardChief Financial OfficerFrèdèrique MenzaghiChief Scientific Officer, Senior VP-R&DJoana GoncalvesChief Medical OfficerScott M. TerrillionSecretary & Chief Compliance OfficerKey CompetitorsPepGenNASDAQ:PEPGVaxxinityNASDAQ:VAXXVerrica PharmaceuticalsNASDAQ:VRCAAtea PharmaceuticalsNASDAQ:AVIROrganogenesisNASDAQ:ORGOView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 1,978 shares on 3/15/2023Ownership: 0.086%B. Riley Wealth Advisors Inc.Bought 1,978 shares on 2/21/2023Ownership: 0.086%Alliancebernstein L.P.Bought 3,641 shares on 2/16/2023Ownership: 0.101%Legal & General Group PlcBought 2,269 shares on 2/15/2023Ownership: 0.200%State of Wisconsin Investment BoardBought 1,807 shares on 2/15/2023Ownership: 0.085%View All Insider TransactionsView All Institutional Transactions CARA Stock - Frequently Asked Questions Should I buy or sell Cara Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CARA shares. View CARA analyst ratings or view top-rated stocks. What is Cara Therapeutics' stock price forecast for 2023? 6 brokers have issued 12 month target prices for Cara Therapeutics' shares. Their CARA share price forecasts range from $6.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 238.0% from the stock's current price. View analysts price targets for CARA or view top-rated stocks among Wall Street analysts. How have CARA shares performed in 2023? Cara Therapeutics' stock was trading at $10.74 at the beginning of the year. Since then, CARA shares have decreased by 53.2% and is now trading at $5.03. View the best growth stocks for 2023 here. Are investors shorting Cara Therapeutics? Cara Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 5,140,000 shares, a decline of 6.4% from the February 28th total of 5,490,000 shares. Based on an average daily trading volume, of 588,000 shares, the short-interest ratio is currently 8.7 days. Currently, 12.2% of the shares of the stock are sold short. View Cara Therapeutics' Short Interest. When is Cara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our CARA earnings forecast. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.34. The biopharmaceutical company had revenue of $20.27 million for the quarter, compared to analysts' expectations of $15.74 million. Cara Therapeutics had a negative net margin of 204.16% and a negative trailing twelve-month return on equity of 45.46%. During the same quarter in the previous year, the company posted ($0.35) earnings per share. What ETFs hold Cara Therapeutics' stock? ETFs with the largest weight of Cara Therapeutics (NASDAQ:CARA) stock in their portfolio include Amplify Seymour Cannabis ETF (CNBS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO) and iShares U.S. Pharmaceuticals ETF (IHE).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY). What is Cara Therapeutics' stock symbol? Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA." Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.89%), Geode Capital Management LLC (1.60%), Pinnacle Associates Ltd. (1.32%), Pinnacle Associates Ltd. (1.28%), Bank of America Corp DE (1.25%) and Morgan Stanley (0.92%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly. View institutional ownership trends. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cara Therapeutics' stock price today? One share of CARA stock can currently be purchased for approximately $5.03. How much money does Cara Therapeutics make? Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $271.32 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. How can I contact Cara Therapeutics? Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510. This page (NASDAQ:CARA) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.